Skip to main content

April 2023, Vol 13, No 4

Big business has been investing billions of dollars per year into healthcare, and, if successful, it may make private practices and community hospitals anachronistic. Read More ›

During the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, a panel of experts identified some of the key challenges to achieving health equity in bladder cancer care and discussed what can be done to improve access to clinical trials, mitigate financial toxicity, and promote value-based care. Read More ›

A new report released by the American Cancer Society (ACS) shows that the incidence of colorectal cancer is rapidly increasing among younger individuals, and the disease is also being diagnosed at more advanced stages in people of all ages. Read More ›

Numerous changes need to be made to raise public awareness of the fact that drinking alcohol raises the risk for several types of cancer. That is a key conclusion from a new study conducted by a National Cancer Institute research team. Read More ›

The FDA has updated its mammography regulations to require reporting of breast density information by facilities, according to a statement by the organization on March 9, 2023. Read More ›

The Health Sector Coordinating Council Cybersecurity Working Group and the US Department of Health and Human Services jointly released a guide to help the public and private healthcare sectors align their cybersecurity programs with the National Institute of Standards Technology Cybersecurity Framework. Read More ›

On March 22, 2023, the FDA granted accelerated approval to retifanlimab-dlwr (Zynyz; Incyte Corporation), a programmed cell death 1–blocking antibody, for the treatment of adult patients with metastatic or recurrent locally advanced Merkel-cell carcinoma. Read More ›

On March 16, 2023, the FDA approved dabrafenib (Tafinlar; Novartis) in combination with trametinib (Mekinist; Novartis) for the treatment of pediatric patients aged ≥1 year with low-grade glioma that harbors a BRAFV600E mutation and who require systemic therapy. Read More ›

On March 3, 2023, the FDA approved abemaciclib (Verzenio; Eli Lilly) plus endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer at high risk for recurrence. Read More ›

On February 9, 2023, the FDA approved dostarlimab-gxly (Jemperli; GlaxoSmithKline) for the treatment of adult patients with mismatch repair-deficient, recurrent or advanced endometrial cancer, as determined by an FDA-approved test, whose disease has progressed on or following a previous platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation. Read More ›

Page 1 of 2